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ABSTRACT 
Hemorrhagic septicemia is caused by gram-negative bacterium 
of Pasteurella multocida (P. multocida) strains. Most of the 
current vaccines against P. multocida have shortcomings. 
Presently, there is increasing efforts towards construction of 
recombinant clone for vaccine development against P. 
multocida. In this review an effort is made to look at some 
strong candidate genes, different protein bands from virulent 
strains and recent reported recombinant antigens. The 
possibility of developing a broad spectrum or cross protection 
vaccine for P. multocida is also discussed. It is hoped that with 
the current development of three (3) completed genome 
sequence of P. multocida, stronger potential immunogens with 
broader spectrum will be identified. Furthermore whole genome 
sequence of other P. multocida strains will surely bridge the 
gap between diagnosis and vaccine development. 
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INTRODUCTION   
Haemorrhagic septicaemia (HS) is caused by the gram-
negative bacterium P. multocida (Tabatabai et al., 2007).  The 
infection can be seen in both humans and animals with varying 
type of pathogenicity. In human it can be seen in soft tissue 
infection especially in elderly and immuno-compromised 
individuals (Baillot et al., 2011). In animals, infection occurs due 
to ingestion of infected grass and water or inhalation. 
Haemorrhagic septicaemia (HS) is an acute and often fatal 
disease primarily occurring in water buffaloes and cattle, but 
occasionally in other domesticated and wild mammals (De 
Alwis, 1999). HS contributes to high rate of mortality in 
livestock animals, where it can spread among endemic and 
non-endemic area. Huge economic loss has been caused by 
the disease especially in tropical regions (Shivachandra et al., 
2011). The subspecie of Pasteurella are multocida, septica and 
gallicida (Kuhnert &Korczak,2006).  P. multocida is the major 
subspecie of economic importance and it has been categorized 
into five capsular sero groups and 16 serotypes.  Relationship 
exists between these capsular types and pathogenicity (Boyce 
& Adler, 2000). The sero groups identified are A, B, D, E and F. 
These serogroups were detected among the livestock 
population (Kumar et al., 2004). Serotypes B: 2 and E: 2 are 
two common serotypes of P. multocida associated with disease 
in animals in Asia and Africa, respectively (Benkirane & De 
Alwis., 2002). Other sero groups afflict different species and 
may vary in virulence factors (Harper et al., 2006). HS 
associated with serotype B:2 are distributed widely in Asia 
(Ataei et al., 2009; Hajikolaei et al., 2008). Buffaloes are more 
susceptible to HS than cattle (De Alwis., 1999). Studies by 
Ewers et al., (2006) have shown that most of the virulence-
associated genes in P. multocida are regularly distributed 
among strains from different hosts and disease status. 
Presently researchers are taking different approaches towards 
the control and spread of the disease, including the 
development of subunit vaccine, using native or recombinant 
antigens (Hatfaludi et al., 2010; Shivachandra et al., 2011). 
This review is aimed at discussing various virulent factors and 
recombinant proteins. The possibility of determining the 
strongest candidate genes/proteins for vaccine development is 
also discussed.  
 
Virulent Factors 
The development of a strong antigenic agent needs proper 
understanding on different virulent factors. Among the virulent 
factors is the outer membrane protein which includes the 
porins, receptors, and pores. Some of the outer membrane 
proteins are called porins due to their role in cellular 
permeability (Benz, 1988). It has been reported that pathogenic 
bacteria produce more vesicles than their nonpathogenic 
counterparts (Liu et al., 2012). The secretion by gram negative 
pathogenic bacteria enables it survives in its host cell. The 
Lipopolysaccharides (LPS) are also included as part of the 
virulent factors. Another virulent factor is the capsules which 
have been known to cause HS in buffalos. The classification of 
P.  multocida into capsular types is based on their composition 
and they play a pivotal role in pathogenicity. Other virulence 
factors include the fimbrae which has been isolated from P. 
multocida serotype A, B and D with ability to adhere to mucosal 
epithelium (Ruffalo et al., 1997). Extracellular enzymes such as 
the hyaluronidase lipase, and neuraminidase or sialidase are 
associated with virulence of P. multocida (Ruffalo et al., 1997).   




Live-attenuated micro-organisms, inactivated bacteria, purified 
microbial components, polysaccharide- carrier protein 
conjugates, recombinant proteins or DNA are used as vaccines 
(Freddy et al., 2004). One of the most widely used vaccines in 
Asia is the whole cell formalin killed P. multocida P52 bacterin 
emulsified in aluminium hydroxide gel (Qureshi & Saxena, 
2014). This vaccine being used, however, does not provide 
long immunity (Qureshi & Saxena, 2014). It is therefore obvious 
that there are difficulties being encountered in producing 
vaccines for P. multocida this may be due to the high antigenic 
variability and low reported work on whole genome sequence. 
In addition the development of vaccines involves the detailed 
understanding of the mechanisms and mode of action of those 
virulent factors. Various studies have shown inconsistent 
efficacy of these vaccines (Moiser et al., 1994). Other 
challenges being encountered in the determination of a strong 
candidate gene from the pool of potential genes discovered, is 
the need to test the protective properties on animal model. 
Furthermore potential gene products or protein will have to be 
purified and characterized before its antigenic properties can 
be fully known. 
 
The use of recombinant technology for vaccine development 
may soon revolutionize the current vaccines. Recombinant 
antigens can be obtained from different expression systems 
after the targeted antigen has been determined. Recombinant 
proteins used as subunit vaccines have been reported safe as 
they are not pathogenic (Verma & Jaiswal, 1998; De Alwis, 
1999).  At present, there is no commercial recombinant HS 
subunit vaccine (Hussaini et al., 2012). The cross-protective 
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Therefore recombinant technology seems promising and may 
be used to develop an efficient vaccine towards protection 
against most strains of P. multocida. Stronger and broad 
spectrum vaccine through identifying conserved immunogenes 
can be achieved from various identified strains of P. multocida.  
 
Candidate Genes  
Several candidates genes against P. multocida. vaccines have 
been reported (Table 1). The stronger candidate genes having 
more resistant protection can be cloned or fused via 
recombinant technology to generate a stronger and more 





Table 1: Potential candidate genes  






















































Tabatabai et al., 2004,  Chomnawang et al., 
2009  & Wu et al., 2007 
Rimler, 2001,  
Wu et al., 2007,  
 
Champlin et al., 2002  and Nsofor et al., 
2006 
 
Nsofor et al., 2006 
PMT P. multocida toxin 146 A, D Frandsen et al., 1991; 
Williamson, 1994 






Outer membrane protein H 
 
Outer membrane protein 
 












Dabo et al., 2007 
Shivachandra et al., 2013. 
Boyce et al., 2006 
 
Pati et al., 1996 
 
Ptfa Type IV fimbrial subunit protein 14.9 A,B,D and 
F 
 
Hatfaludi et al., 2010 
 
A total of 100 virulent genes in P. multocida have been 
reported (May et al., 2001). One of the major candidate genes 
is the PMT gene.  A study have confirmed that the toxigenicity 
of P. multocida is mainly derived from PMT, the PMT is 
encoded by tox A gene, establishing the fact that Tox A 
knockout gene contributes the major part of the toxigenicity of 
P. multocida (Kim et al., 2006). Non Toxigenic P. multocida 
toxin (PMT) was created as candidate for use in vaccines 
against progressive atrophic rhinitis in pigs, this was done by 
replacing the serine at position 1164 with alanine (S1164A) and 
the cysteine at position 1165 with serine (C1165S) as such 
genetically modified PMT may represent a good candidate for 
use in developing a vaccine against progressive atrophic 
rhinitis in pigs. (Shivachandra et al., 2005). Another putative 
candidate gene is the ompA gene (encoding an outer 
membrane protein) has also been reported to be involved in the 
adherence of P. multocida to host cells (Dabo et al., 2003; 
Hatfaludi et al., 2010). Several other Omp’s have been 
identified including Omp16, Omp87 and iron-regulated OMPs 
such as TbpA, HemR, HbpA, HasR, HgbA (Wheeler et al., 
2009). Analysis of Omph from different serotypes showed a 
high degree of conservation (Meredith et al., 2000). OmpH was 
shown to be of importance in stimulating immunity to infection  
 
in animals (Davies & Lee, 2004). OmpA proteins are under  
 
evaluation as potential vaccine candidates (Shivachandra et 
al., 2013). The OmpA, will be a favorable gene for the 
development of naturally and recombinant-derived vaccines 
(Shivachandra et al., 2013). 
 
The ptfA gene has also been proven to have a positive 
association with the disease outcome in cattle and hence could 
be used to develop broad cross-protective and disease specific 
subunit vaccine along with suitable adjuvants especially for HS 
in bovines and septicaemic pasteurellosis in sheep and goat 
(Shivachandra et al., 2013).  Among the proposed candidate 
gene is the plpB gene, although controversies have surrounded 
the acceptance of the plpB as a candidate gene for the 
development of P. multocida vaccine. It was first purified and 
proved to confer protection against different serotypes of PM 
(Rimler, 2001). The protein was confirmed to be P. multocida 
lipoprotein B by Tabatabai & Zehr (2004).  Other reported 
candidate genes include the Aro A gene, as deletion of Aro A 
(A gene encoding the P. multocida toxin) of sero type B2 was 
used as an effective vaccine against HS (Ataei et al., 2009). 
Another candidate gene is the CexA gene mutant (PBA875) 
which conferred high protection against P. multocida infection 
(Boyce et al., 1991). Furthermore, one of the genes predicted 
to be involved in polysaccharide biosynthesis (bcbH gene) has 
been shown to confer significant protection against wild type 
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after immunization of mice with the live AL18 strain (Boyce & 
Adler, 2001). Other reported virulent genes are tbpA and pfhA 
as well as capsule biosynthesis genes are supposed to be 
important epidemiological marker genes for characterizing P. 
multocida field strains (Ataei et al., 2009). Study by Ewers et 
al., (2006) confirmed that tbpa and pfha are virulent genes. The 
TbpA gene (82 kDa protein) first isolated in haemorrhagic 
septicaemia (HS) strains of capsule serotype B: 2, 5 in 
buffaloes and cattle (Veken et al., 1994) have been shown to 
have strong homology with A1 and D1 (Shivachandra et al., 
2005). 
 
Recent study by Verma et al., (2013) found high occurrence of 
pfhA and tbpA genes among P.multocida isolates from 
diseased as well as healthy cattle. Some virulence associated 
genes such as sodA & sodC were found in a higher percentage 
among isolates from diseased animals as compared to isolates 
obtained from apparently healthy animals (Verma et al., 2013). 
A work carried out by Shivachandra et al.,(2013) suggests that 
a recombinant OmpH (a gene for outer membrane protein H) 
might be a useful vaccine candidate.  Surface exposure and 
high number of copy makes the OmpA-like proteins favourite 
candidates for vaccine development (Shivachandra et al., 
2013). The recent development of recombinant manipulation 
systems together with the availability of multiple genome 
sequences may help to explain the association of these genes 
with pathological conditions in a given host, as well as helping 
to elucidate pathogenic mechanisms (Wilkie et al., 2012). 
Currently recombinant technology is revolutionizing the world of 
vaccine development.  
 
Protein Bands From Pathogenic Strains 
Most of the reported proteins have been identified by their band 
patterns. Protein band patterns can serve as a guide towards 
effective vaccine developments. Presently more than 60 
different outer membrane proteins (OMP) of different strains 
have been reported to play a role in pathogenesis and 
immunity (Hatfaludi et al., 2010). Relationship between 
electrophoretic pattern and serotype properties of isolates have 
been reported (wheeler, 2009). One of the most identified 
proteins is the PM toxin which has been fully characterized; it is 
a monomeric protein with the N-terminal region containing the 
binding and translocation domain that leads to its endocytosis 
(Baldwin et al., 2004). Amongst the bands reported were seven 
polypeptide bands of different molecular weights obtained P. 
multocida, the protein ranges from 36.31 kDa to 104.71 kDa 
(Numan et al., 2008). Results showed that all the isolates 
belonged to the same serotype (Numan et al., 2008); the 51.29 
and 36.31 kDa bands were thick and were recognized as major 
bands of P. multocida whole strain protein. Other bands 
obtained were 60.26, 69.18, 77.62, 85.11, and 104.71 kDa 
(Numan et al., 2008), but according to Sridevi et al., (1999), 13 
bands were obtained from P. multocida whole cell on SDS-
PAGE analysis among which 61.27 kDa and 26 kDa bands 
were major bands.  
 
Another study have reported 5 bands from P. multocida, the 
bands were 27, 32, 35, 37 and 44 kDa (Johnson et al., 1989). 
However studies with different strains of P. multocida by Lee et 
al., (1991) suggested that there were no serotype specific band 
patterns with regard to protein and carbohydrate moieties of 
avian isolates on SDS-PAGE. This is in line with study of 
Numan et al., (2008). There are several other works done on 
protein pattern from P. multocida that contributes towards 
identifying a candidate protein and may guides to cloning the 
gene that encodes the protein. Dabo et al., (1997) for example, 
reported eight major outer membrane proteins with two major 
proteins of 35 kDa and 46 kDa molecular weights by SDS-
PAGE of bovine P.multocida isolated from cattle and pig 
sources.  Pati et al., (1996) also observed ten polypeptide 
bands having molecular weights of 88 kDa to 25 kDa, amongst 
these 44.37 kDa and 30 kDa bands were considered as major 
immunogens. Eight protein bands (94, 84, 53.5, 49, 43, 41, 
29.5 and 16 kDa) on SDS-Page analysis have been reported 
(Morton et al., 1996). The protein band of molecular weight 43 
kDa was present in all serovars. 
 
Several other works (Ireland et al., 1991; Lee et al., 1991; 
Syuto & Matsumoto, 1982) suggested that the number of 
protein and carbohydrate bands resolved on SDS-PAGE were 
different from one study to another and that may be attribued to 
the type and strain of the antigen.  
 
Studying these proteins and their band patterns as well as 
comparative analysis may therefore open a new way towards 
vaccine development especially with announcement of more 
whole genome sequence of P. multocida. It is more than 10 
years now since the establishment of more genome sequence 
result of P. multocida (May et al., 2001) however; most of these 
proteins remain uncharacterized (Boyce et al 2012). The few 
characterized proteins of outer membrane are OmpH, OmpA, 
P6-like protein, PlpB, GlpQ, Lpp and Oma78 (Boyce et al. 
2006). OmpH is the best characterised among them. It was 
found to be present in basically all bovine isolates (Dabo et al., 
2007). Verma et al., (2013) have suggested that more studies 
needs to be centered on role of these genes in health and 
disease and how their expression is or can be influenced and 
regulated under immunosuppression. 
 
Recent Development On Recombinant Clones Towards 
Subunit Vaccines 
Recent recombinant effort toward recombinant vaccine 
development by researchers (Table 2) may probably yield 
positive result for the next generation vaccines. A laboratory 
study by Hussaini et al., (2011) have shown that a recombinant 
clone of ABA 392 obtained from P. multocida strain (B: 2) could 
have a strong potential for vaccine development. Two 
immunogenic fussion (OmpH and OmpA) was done recently by 
Gong et al 2013, and suggested they may have 
immunogenicity and efficacy of immune protection against fowl 
cholera. Fusion between OmpA and OmpH vaccine may bring 
promising result and, provide a valuable reference for the 
designing of future DNA vaccines for avian P. multocida (Gong 
et al., 2013). Most recent work published by Shivachandra et 
al., 2014, indicated potential possibilities of using absolutely 
conserved vacj gene (coding for outer membrane lipoprotein) 
either as ‘signature gene/protein’ in developing diagnostic 
assay or as a recombinant subunit vaccine for P. multocida 
infections in livestock.  Filamentous hemagglutinin (FHAB2) is 
one of the candidate virulent factors, a recombinant protein of 
FBAH2 derived from P. multocida serotype A: 3 and has been 
shown to have a significant protection against lethal challenge 
with P. multocida (Johnson et al., 2013). A product of plpB 
gene (63kDa) consisting of 831bp has been proven to provide 
20–30% protection against P. multocida serotype A: 1 and A: 3, 
4 infections. The plpB protein may not be an appropriate target 
as a candidate subunit vaccine for P. multocida infection 
(Chomnawang et al., 2009).  It may be possible to have a 
higher yield of protection of the plpB gene product by fussion 
with another strong candidate gene. Other researchers are 
currently paying attention to the use of DNA obtained from 
outer membrane gene of P. multocida as vaccines (Singh et al., 
2011; Okay et al., 2012).  
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921 26 B:202 Mice 90 Hussain et al., 
2012. 




















rOmp87 102 87 B:2 Cattle, buffalo, sheep, 
goat, pig rabbit, 
chicken, duck, quail, 
turkey, goose leopard 
and deer 
66.6 Kumar et al., 2014. 
plpE + OmpH 474 + 969 35+17 A:3 Mice 40 Okay et al., 2012. 
PMT2.3  2300 146 D Fowl High level Lee et al., 2012. 
LKTA + PlpE + 
inactivated 
bacterin  
846 + 1014 30.9 + 38.4 A:1 and A:6 Rabbit and sheep 100 Guzmán-Brambila 
et al.,2012 
pPtfA 414 31 B Pigs, sheep and goats N/A Shivachandra et 
al., 2012. 
plpB 831 63 A Mice 20-30 Chomnawang et 
al., 2009.   
pOMPH + 
pOMPA 
1047 +1050 N/A 
(transfection) 
CVCC474 Chickens 70 Gong et al., 2013. 
N/A = Not applicable 
 
The first report of a recombinant P. multocida antigen that 
confers cross protection on animals was reported by Wu et al., 
2007, using a recombinant clone of PlpE and PlpB gene from 
strain of P. multocida X-73. Several genes are however yet to 
be tried as recombinant subunit vaccines. Genes with strong 
homology or conserved sequences may likely be a good 
candidate for broad spectrum recombinant vaccine 
development.  
 
Whole Genome Sequence Of Pasteurella Multocida 
Success for vaccine development depends largely on the 
availability of several whole genome sequences of different 
strains of P. multocida. Presently three (3) P. multocida species 
have been fully sequenced (Table 3). It is of importance to  
mention that the current complete sequenced genome of P. 
multocida ranges between 2 and 2.4Mbp with G+C content of 
between 40 and 41% (Boyce et al., 2012). The complete 
pathogenesis of haemorrhagic septicaemia is still an enigma.  
 
Currently, only four complete genome sequences of P. 
multocida subsp. Multocida strains are available, those for 
Pm70 (GenBank accession number AE004439), 3480 
(accession number CP001409), HN06 (accession number 
CP003313), and 36950 (accession number CP003022), which 
belong to serotypes F, A, D, and A, respectively (Huan et al., 
2013). With the subsequent unraveling of more complete 
genome sequence of P. multocida, the exact virulence factor of 
the pathogenicity of this organism may soon be clear. The 
elusive determinants of cross-protective immunity still pose a 
substantial challenge to the scientific community (Shivachandra 
et al., 2011). 
 
 
Table 3: Completed whole genome sequence some species of P. multocida 
PM  Strain Genomic Size Reference 
HN06 D 2.4Mb Liu et al., 2012. 
PM70                                                A:3
 
2.25Mb May et al., 2001. 
                                                               




Michael et al., 2012. 
 
There are other incomplete (Draft) whole genome sequences 
such as the P2095, AnanD1 and X73 (Johnson et al., 2013) 
and VP161 , M1404 (B:2) and P903 (D:11), PBA100  A:1, 1059 
(Ireland et al., 1991) . The draft genome has recently been 
reported of PMTB (Huan et al., 2013) with 2.20Mb of serotype 
B: 2. Even though the pace in the complete whole genome 
sequence analysis has been very slow, but it is hoped that in 




There is inconsistency with the development of vaccines; 
this might probably be due to the heterogeneity of P. 
multocida. It is therefore important to develop an efficient 
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vaccine towards protection against most strains of P. 
multocida. Most of the currently used bacterial vaccines 
do not confer full protection; as such more effort is 
required for the development of better vaccines. A 
possible challenge towards the use of recombinant 
technology for vaccines development is that the cloned 
copy of the gene might not fully expressed it proteins as 
such making the development of the vaccine difficult. 
Different strains of pathogenic bacteria poses a bigger 
challenge in vaccine development, as some vaccines may 
not really be protective against all strains. It should be 
noted that targeting conserved regions of various strains 
can be more effective for cross protective vaccines 
development. Gene expression and characterization of 
proteins will aid proper diagnosis and antigen 
determination. Gene expression profiling needs to be 
carried out on reported candidate or virulence genes to 
ascertain the pathogenicity to their host. Genome 
sequencing of more P. multocida specie can help to 
bridge the gap in antigen determination. Single Nucleotide 
polymorphisms can further be studied of the virulence 
genes as well as understanding their regulatory and 
transcriptional factors.  
  
The use of microarray may aid faster diagnosis. Linkage 
analysis between virulent genes may seem promising in 
the effort to streamline and identify association of virulent 
genes in pathogenicity. With the current research trend, it 
is hope that recombinant vaccine against heterologous 
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